EWS-GARCH: New Regime Switching Approach to Forecast Value-at-Risk
Central European Economic Journal · 2018
DOI: 10.1515/ceej-2017-0014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Central European Economic Journal, 2018. Verfasst von Marcin Chlebus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In the study, the two-step EWS-GARCH models to forecast Value-at-Risk is presented. The EWS-GARCH allows different distributions of returns or Value-at-Risk forecasting models to be used in Value-at-Risk forecasting depending on a forecasted state of the financial time series. In the study EWS-GARCH with GARCH(1,1) and GARCH(1,1), with the amendment to the empirical distribution of random errors as a Value-at-Risk model in a state of tranquillity and empirical tail, exponential or Pareto distributions used to forecast Value-at-Risk in a state of turbulence were considered. The evaluation of Value-at-Risk forecasts was based on the Value-at-Risk forecasts and the analysis of loss functions. Obtained results indicate that EWS-GARCH models may improve the quality of Value-at-Risk forecasts generated using the benchmark models. However, the choice of best assumptions for the EWS-GARCH model should depend on the goals of the Value-at-Risk forecasting model. The final selection may depend on an expected level of adequacy, conservatism and costs of the model.
Zitieren
APA
Chlebus, M. (2018). EWS-GARCH: New Regime Switching Approach to Forecast Value-at-Risk. Central European Economic Journal. https://doi.org/10.1515/ceej-2017-0014
Vancouver
Chlebus M. EWS-GARCH: New Regime Switching Approach to Forecast Value-at-Risk. Central European Economic Journal. 2018. doi:10.1515/ceej-2017-0014
BibTeX
@article{Chlebus2018,
author = {Chlebus, Marcin},
title = {EWS-GARCH: New Regime Switching Approach to Forecast Value-at-Risk},
journal = {Central European Economic Journal},
year = {2018},
doi = {10.1515/ceej-2017-0014}
}
EUVIMED